Wednesday, July 30th34.8°C
22568
22412

Drugmaker Merck's Q4 profit, sales fall due to generic competition, unfavourable exchange rates

Merck & Co.'s fourth-quarter profit dropped 14 per cent, with its aggressive cost cutting not enough to offset restructuring charges, generic competition to former blockbuster medicines and unfavourable currency exchange rates.

Results just missed Wall Street expectations, and even though Merck said 2014 will be a "trough year" for revenue, shares briefly hit a six-year high of $55.20. That's because the world's third-biggest drugmaker separately announced new, potentially lucrative alliances.

Merck will collaborate with three other drugmakers to test its hot experimental cancer drug, called MK-3475, in combination with theirs. It's in a new class of cancer medicines meant to restore the immune system's natural ability to spot and target cancer cells.

In morning trading, Merck shares rose $1.05, or 2 per cent, to $54.56.

Merck reported net income of $781 million, or 26 cents per share, down from $908 million, or 30 cents per share, a year earlier.

The maker of the Type 2 diabetes pill Januvia said that excluding one-time items, net income was $2.6 billion, or 88 cents per share — a penny shy of analysts' expectations.

Revenue totalled $11.32 billion, down 4 per cent. Analysts expected $11.36 billion.

Sales were lower than expected for Januvia, HPV vaccine Gardasil and a few other products, but higher than expected for immune disorder drug Remicade, HIV drug Isentress and cholesterol pills Zetia and Vytorin.

Two issues dominated Merck's conference call with analysts. Asked about MK-3475's potential, as a solo treatment and combined with drugs from new partners Pfizer Inc., Amgen Inc. and Incyte Corp., Merck said it's too soon to tell.

Analysts also asked about Merck's strategic review of its animal health business, the world's second largest, and its consumer health business, which sells Coppertone sun care items and nonprescription Claritin allergy pills. CEO Kenneth Frazier said he's determining whether they'd be more valuable inside or outside of Merck and will decide by year's end.

Bernstein Research analyst Dr. Timothy Anderson wrote that he thinks Merck might keep animal health, which Frazier said he likes for a number of reasons, rather than consumer health, which is limited by small size. Swiss drugmaker Novartis AG reportedly is weighing deals including swapping its animal health business for Merck's consumer segment.

Merck, based in Whitehouse Station, N.J., forecast 2014 profit of $3.35 to $3.53 per share, excluding one-time items. Analysts are projecting $3.46 per share.

For all of 2013, Merck reported net income of $4.04 billion, or $1.47 per share, on revenue of $44.03 billion.

___

Follow Linda A. Johnson at http://twitter.com/LindaJ_onPharma

The Canadian Press


Read more Business News




Recent Trending




Today's Market
S&P TSX15524.82+78.271
S&P CDNX1011.10-5.40
DJIA16880.36-31.75
Nasdaq4462.902+20.204
S&P 5001970.07+0.12
CDN Dollar0.9170-0.0001
Gold1310.00+6.70
Oil99.41-0.86
Lumber327.40+5.10
Natural Gas3.73-0.017

 
Okanagan Companies
Pacific Safety0.1850.00
Knighthawk0.01-0.005
QHR Technologies Inc1.22+0.02
Cantex0.085+0.02
Anavex Life Sciences0.26-0.0075
Metalex Ventures0.08-0.005
Russel Metals35.22-0.07
Copper Mountain Mining2.83-0.03
Colorado Resources0.22-0.005
ReliaBrand Inc0.10+0.019
Sunrise Resources Ltd0.03-0.005
Mission Ready Services0.15-0.005

 





FEATURED Property
193563814991 East Hill Road
2 bedrooms 1 baths
$997,000
more details
image2image2image2
Click here to feature your property
Please wait... loading


Take charge of your debt

Photo: Thinkstock.comWays to reduce your Debt:Make a budget and get budget counselingA basic first step for debt reduction is to prepare a budget and plan your spending. Once you have a budget, you mu...


Geopolitical tensions rattle markets

The Big Picture Geopolitical tensions rattle markets The spectre of rising geopolitical tensions in Ukraine and Gaza cast a shadow over an otherwise positive week in the markets. News that a passenger...


Learn to delegate effectively

Photo: ContributedI have the pleasure of witnessing people delegate tasks quite often. Sometimes with tremendous success and sometimes with disastrous consequences. I have chaired a lot of committees...

_








Member of BC Press Council


22461